Impact of a pharmacist-led adalimumab biosimilar interchange protocol on order processing time

Key Points

• This research aims to assess the effectiveness of a pharmacist-led interchange protocol on biosimilar processes.
• Utilized a pharmacist-led interchange protocol for adalimumab biosimilars.
• Measured order processing time before and after protocol implementation.
• The pharmacist-led protocol improved order processing time.
• Indications suggest a need to evaluate discontinuation rates for adalimumab products.